Succinate Buffer in Biologics Products: Real-world Formulation Considerations, Processing Risks and Mitigation Strategies.

The succinic acid/succinate system has an excellent buffering capacity at acidic pH values (4.5-6.0), promising to be a buffer of choice for biologics having slightly acidic to basic isoelectric points (pI 6 - 9). However, its prevalence in drug products is limited due to the propensity (risk) of its components to crystallize during freezing and the consequent shift in the pH which might affect the product stability. Most of these previous assessments have been performed under operational conditions that do not simulate typical drug product processing conditions. In this work, we have characterized the physicochemical behavior of succinate formulations under representative pharmaceutical conditions. Our results indicate that the pH increases by ∼ 1.2 units in 25 mM and 250 mM succinate buffers at pharmaceutically relevant freezing conditions. X-ray diffractometry studies revealed selective crystallization of monosodium succinate, which is posed as the causative mechanism. This salt crystallization was not observed in the presence of 2% w/v sucrose, suggesting that this pH shift can be mitigated by including sucrose in the formulation. Additionally, three monoclonal antibodies (mAbs) that represent different IgG subtypes and span a range of pIs (5.9 - 8.8) were formulated with succinate and sucrose and subjected to freeze-thaw, frozen storage and lyophilization. No detrimental impact on quality attributes (QA) such as high molecular weight (HMW) species, turbidity, alteration in protein concentration and sub-visible particles, was observed of any of the mAbs tested. Lastly, drug formulations lyophilized in succinate buffer with sucrose demonstrated acceptable QA profiles upon accelerated kinetic storage stability, supporting the use of succinate buffers in mAb drug products.

Assembly Dynamics of Plasmonic DNA-Capped Gold Nanoparticle Monolayers.

The self-assembly of nanoparticles in aqueous solutions promises wide applications but requires the careful balance of many parameters not present in organic solvents. While the presence of long-range electrostatic interactions in aqueous solutions may complicate such assemblies, they provide additional parameters through which to control self-assembly. Here, with DNA-capped gold nanoparticles and through the variation of the ionic strength in aqueous solutions, we explored the influence of electrostatic interactions on the adsorption of negatively charged nanoparticles on a positively charged surface. Specifically, we studied the kinetics of nanoparticle adsorption from solution using the quartz crystal microbalance with dissipation (QCM-D). We also characterized the structure of the adsorbed monolayers employing a combination of grazing incidence small-angle X-ray scattering (GISAXS) and scanning electron microscopy. We discovered that adsorption kinetics and monolayer structure were under the control of the DNA ligand length, solution ionic strength, and salt species. We also precisely fit the kinetics to a modified Langmuir model, which converged to the simple Langmuir model at high ionic strengths of magnesium chloride. We demonstrated that increasing the ionic strength and decreasing the DNA ligand lengths increased the surface coverage while decreasing the nanoparticle-nanoparticle spacing. The DNA-capped nanoparticle system reported here provides a readily applicable platform for controlling nanoparticle self-assembly in aqueous solution. Finally, we employ this tunability to create a system with a tunable plasmonic response. Our kinetics studies of the assembly process and further characterizations undertaken will facilitate the construction of nanoparticle arrays with precise structure, and such control will aid in the design of future plasmonic and optoelectronic devices.

Angioimmunoblastic T-Cell Lymphoma Presenting with an Acute Serologic Epstein-Barr Virus Profile.

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma typically characterized by prominent lymphadenopathy and B-symptoms at the time of presentation, polyclonal hypergammaglobulinemia, autoimmune hemolysis and frequent but highly variable involvement of Epstein-Barr virus (EBV). Lymph node biopsy findings typically include effacement of nodal architecture, polymorphic infiltrate, atypical T-cells (usually CD4+/CD10+/PD1+) and prominent proliferations of high endothelial venules and follicular dendritic cells. However, this classic constellation of pathologic findings is often initially obscured by a prominence of EBV+ B-immunoblasts with or without associated peripherally circulating EBV DNA. Here we document the first reported case of an acute serologic EBV profile (VCA-IgM) in a patient with AITL, and we recommend that clinicians maintain a high index of suspicion for AITL in the appropriate clinical scenario, irrespective of Epstein-Barr related findings.